Third Avenue Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A GLP-1 advertisement can establish that a company offers access to treatment. It cannot, by itself, establish how well that company’s particular preparations work. Third Avenue illustrates that distinction: its public pages describe injectable compounded semaglutide and tirzepatide, online assessment, ongoing support and home delivery. Those are meaningful service details. They are not measured clinical outcomes for its patients, nor do they establish that its formulations reproduce results from trials of specific studied products.

This review examines Third Avenue’s public documentation consulted October 19, 2026, separating documented service arrangements from clinical evidence and unresolved commercial claims. The central finding is not simply that information is missing. Several important details are published, including medication prices, an annual membership charge and refund boundaries. But different pages describe different billing intervals, shipping services and deadlines for reporting delivery problems. Those differences deserve clarification before payment, alongside questions about the preparation and pharmacy actually assigned.

At a glance

Who provides care: Third Ave LLC operates the platform; its terms assign healthcare services to MDI Medical Group PC and applicable affiliated professional entities, not Third Avenue itself.
Sources: [13]
Advertised medication charges: Product pages advertise compounded injectable semaglutide at $49/month and tirzepatide at $68/month, at any dose, plus membership after the trial. They also display unexplained $98/month and $135/month figures.
Sources: [6] [10] [11]
Membership is separate: The seven-day free trial covers membership only. Medication is charged during the trial; membership continues at $199/year unless canceled before the trial ends.
Sources: [6]
Product evidence boundary: Third Avenue discloses that compounded medications are not FDA approved. Exact formulation and dispensing pharmacy depend on clinical review, location and fulfillment availability.
Sources: [12] [6]
Conflicting delivery-issue deadlines: The homepage says to report damaged, defective or incorrect products within seven days; the refund policy generally requires immediate reporting and no later than 48 hours after confirmed delivery.
Sources: [8] [7]

Start with the product, not the ingredient name

Third Avenue’s program page advertises prescription semaglutide and tirzepatide injections, while the individual product pages identify them as compounded preparations. The semaglutide page says the exact formulation and dispensing pharmacy depend on clinical review, the patient’s state and current fulfillment availability. That makes the final prescription and pharmacy information more informative than the ingredient name alone. The reviewed documentation does not establish a complete composition, concentration, source manufacturer or documented batch-testing results for every preparation.

Third Avenue appropriately discloses that compounded medications are not FDA approved and do not receive FDA review for safety, effectiveness or quality. FDA’s guidance recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. This is an individualized medical question, not something a low advertised price resolves. Nonapproval alone also does not prove that a preparation is clinically inequivalent to an approved product.

For a reader weighing the offering, the useful evidence request is specific: what preparation would be prescribed, which pharmacy would dispense it, and why is that preparation appropriate? Our guide to approved medicines and compounded preparations explains the distinction. The consulted materials do not justify attributing a particular salt form, ingredient blend or quality-testing practice to Third Avenue. Missing specifications should remain unanswered questions rather than becoming either a safety endorsement or an allegation.

Sources: [11] [6] [12] [1]

The platform, medical group and pharmacy have different jobs

The homepage presents Third Avenue as a telehealth and pharmacy platform handling consultation, prescription and fulfillment in one place. Its terms draw a sharper organizational boundary: Third Ave LLC, a Delaware limited liability company doing business as Third Avenue, is an administrative and technology business. The terms expressly say Third Avenue is not a healthcare provider or pharmacy and does not make diagnosis, treatment, prescribing, medical-necessity or dispensing decisions. Convenience of access should not obscure that division.

Healthcare services are assigned to MDI Medical Group PC and, where applicable, affiliated professional entities. Prescription fulfillment belongs to independent licensed dispensing pharmacies selected according to the prescription, patient location, availability and other operational or legal considerations. No particular pharmacy is guaranteed, and the pharmacy used can change. The consulted documentation does not identify the dispensing pharmacies by name or permit independent confirmation of their licenses, advertised certifications or individual clinicians’ credentials.

The privacy documentation similarly separates clinical records maintained by the medical group and healthcare professionals from Third Avenue’s administrative information. Where available and legally permitted, patients may request that a prescription be sent or transferred elsewhere, but prices, formulations, shipping and services can differ, and some products may not be available. These details illustrate what public provider documents can establish: an allocation of responsibilities, not independent verification of every participant’s performance.

Sources: [13] [8] [9]

Trial evidence does not become Third Avenue outcome evidence

Clinical research provides context for the medicines’ names, but it must remain attached to the product, population and treatment actually studied. STEP 1 studied subcutaneous semaglutide in adults with obesity or overweight plus a weight-related condition, without diabetes. SURMOUNT-1 studied subcutaneous tirzepatide in adults with obesity or overweight plus a weight-related complication, excluding diabetes. Neither was a trial of Third Avenue’s service or the compounded preparation a particular customer would receive.

Third Avenue’s materials include broader promotional themes around body composition, longevity and organ protection. Such claims should not be treated as verified outcomes of this program. The product-page references do not establish identical results for a specific formulation. Likewise, the appearance of “Semaglutide Microdose” in product-page suitability language does not make trial results applicable to an unspecified microdose regimen. Readers should ask which evidence supports the exact formulation, route and intended use under consideration.

The relevant distinction is between evidence that a studied treatment can work and evidence that this provider has documented its own results. The reviewed documentation does not establish provider-specific effectiveness or adverse-event rates. Our explanation of why a clinical trial is not a company performance report develops that boundary. It also prevents an unsupported comparison: separate semaglutide and tirzepatide trials are not a randomized head-to-head test of Third Avenue’s two offerings.

Sources: [6] [10] [11] [3] [4]

Published prices need a billing-calendar explanation

The semaglutide page specifies $49/month for medication at any dose; the tirzepatide page specifies $68/month on the same basis. Both add membership at $199/year after a seven-day free trial. Yet the pages also display $98/month and $135/month, respectively, without documented conditions resolving those alternatives. The lower figures should not be presented as complete treatment prices, and the higher figures should not be interpreted as a defined introductory-discount schedule without supporting terms.

A second issue is the collection interval. The enrollment page explicitly says tirzepatide is billed $68 every 25 days, while other language describes monthly subscriptions renewing at the displayed flat price. Twenty-five days is not a calendar month. The consulted materials do not resolve the discrepancy or establish the exact supply quantity per order. Before checkout, a reader needs the actual medication charge, next collection date and supply details—not an annualized estimate built from inconsistent descriptions.

Commercial terms that should be reconciled before checkout
Item	Published description	Question to resolve
Compounded injectable semaglutide	$49/month at any dose; $98/month also displayed	Which medication charge applies, and under what conditions?
Compounded injectable tirzepatide	$68/month at any dose; $135/month also displayed	How does the selected price relate to the alternative figure?
Collection interval	Monthly language alongside $68 every 25 days	What is the next charge date and the supply per order?
Membership	Seven-day trial, then $199/year; medication charged during trial	When does the annual charge occur, and how is it canceled?
Payment and reimbursement	Cash-pay; no insurance claims submitted or reimbursement guaranteed	What amount must be paid directly, regardless of potential benefits?

Sources: [6] [10] [12] [13]

Online intake is a review process, not prescription approval

Third Avenue advertises a free, fully online assessment covering health history, lifestyle and goals. Its program says eligibility is determined by a licensed clinician and does not rely on BMI alone. The terms require users to be at least 18, or the higher age of majority where they live. These are the provider’s stated access rules, not a promise that completing the questionnaire establishes eligibility or that every requested treatment will be prescribed.

The terms allow a clinician to require synchronous audio-video communication, diagnostic testing, an in-person examination, follow-up care or other information before prescribing or continuing treatment. Although laboratory testing is mentioned, the consulted pages do not establish a mandatory panel, testing frequency or whether all associated costs are included. The semaglutide page says treatment is not recommended for people with a personal or family history of medullary thyroid cancer or MEN2, and that a doctor will assess suitability. That warning is not a substitute for a complete clinician assessment.

The geographic claim is broad but qualified: Third Avenue says telehealth is available to eligible patients physically located in all 50 states, while acknowledging that not every treatment or medication is available everywhere. Location, professional licensure, pharmacy coverage, law, availability and individual eligibility can change access. Someone already prescribed a GLP-1 elsewhere can also seek review of symptoms and response. The documentation does not establish that transferring care automatically preserves an existing prescription, formulation or treatment plan.

Sources: [6] [11] [13] [8]

Follow-up is described more clearly than its timing

Membership is presented as payment for the care surrounding the medication: messaging, continuing check-ins, clinician-led adjustments, member refill pricing and free overnight shipping. Product pages also say plans cover required supplies, delivery and continued clinical oversight. Third Avenue describes its clinicians as U.S. board-certified, but the consulted documentation does not independently verify individual credentials. The useful distinction is between a published service promise and evidence showing how consistently that promise is delivered.

Product pages invite secure messages at any time and describe scheduled physician follow-ups, without establishing a fixed appointment frequency or guaranteed response time. The contact page lists support@thirdavenue.com, 302-428-9872 and care-team hours of Monday through Friday, 8 a.m. to 8 p.m. Eastern. Being able to send a message at any hour therefore should not be read as a promise of immediate clinical attention. The terms also say communications are not monitored for emergencies.

The program describes nutrition support, strength-training guidance, progress tracking and help managing gastrointestinal symptoms. These are substantive advertised components, but their description does not document an outcome advantage for this provider. NIDDK frames follow-up around treatment response and tolerability as well as ongoing care. Before enrolling, readers can ask who handles clinical questions, how follow-up is scheduled and whether any testing or additional encounters fall outside the advertised plan. Spanish-language clinical care or interpretation is not confirmed.

Sources: [6] [8] [5] [11] [13] [2]

Payment precedes review, and refund boundaries arrive early

Third Avenue says payment is collected when an order is placed, before clinical review. If a provider does not approve treatment and no prescription is issued, the homepage promises a full refund. An unfinished intake is different: the refund policy says the request remains pending and the collected payment remains applied to it. Failing to complete the questionnaire does not itself cancel the order, establish clinical denial or trigger an automatic refund.

For an initial order or an order requiring a new prescription, approval plus prescription issuance makes the order final and nonrefundable, subject to policy exceptions. That boundary can occur before the pharmacy receives, accepts, dispenses or ships the prescription. Refills under an existing prescription follow a different rule: they become final when submitted to or accepted for pharmacy processing. The policy provides a refund if cancellation follows the renewal charge but precedes submission for pharmacy processing.

The enrollment page permits cancellation of either recurring charge by emailing support. That does not establish a refund for a finalized medication order or a proportional refund of an annual membership already collected. Ordinary prescription-product returns are not accepted once products leave the dispensing pharmacy. When a refund is due, the policy says it is generally initiated five to ten business days after the determination; a bank may take longer to post it. Cancellation and money returning to an account are separate events.

Sources: [12] [8] [7]

Shipping promises need a usable problem-resolution plan

The homepage describes typical processing within 24–48 hours after prescription approval, with most orders arriving in three to five business days depending on location. Tracking is emailed when the package is on its way. Elsewhere, membership advertises free overnight shipping on every refill, cold-shipped in plain packaging, while enrollment describes free discreet standard shipping. Processing, dispatch, transit service and arrival are different measures. These descriptions do not establish one uniform guaranteed delivery timetable.

The discrepancy becomes more consequential if a product arrives damaged or questionable. The homepage allows seven days after delivery to report damaged, defective or incorrect items. The refund policy instead requires immediate reporting of damaged, defective, incorrect, missing or potentially transit-compromised products and, absent extraordinary circumstances, sets a 48-hour limit after confirmed delivery. That shorter policy deadline should be clarified before purchase rather than assuming the homepage’s longer period will govern a particular claim.

FDA explicitly advises not using an injectable GLP-1 product that arrives warm or inadequately refrigerated, and contacting the provider or dispensing pharmacy. A shipping advertisement cannot establish that an individual package remained within suitable conditions. Our guide to reading cold-chain and delivery claims separates those questions. For Third Avenue, practical preparation means obtaining the dispensing pharmacy’s contact details, understanding the reporting process and knowing which shipping description applies to the actual order.

Sources: [8] [7] [12] [1]

Questions & answers

Is Third Avenue itself my healthcare provider or pharmacy?

Not under its terms. Third Ave LLC operates the administrative platform; MDI Medical Group PC and applicable affiliates provide healthcare, while independent dispensing pharmacies fulfill prescriptions. The homepage’s all-in-one presentation describes coordination, not a single entity performing every role. Ask which clinician and pharmacy will handle your order and whom to contact for clinical, dispensing and billing questions.

Sources: [13] [8]

Does the seven-day trial make the medication free?

No. The trial applies only to membership and begins at checkout. Medication is charged during that period. Unless canceled before the trial ends, membership continues at $199/year, separately from medication charges. The pages advertise $49/month for compounded semaglutide and $68/month for compounded tirzepatide, but alternative displayed prices and inconsistent billing intervals require confirmation before purchase.

Sources: [6] [10] [12]

Can I use insurance, Medicare or an HSA to cover the charges?

Third Avenue describes the service as cash-pay and says it does not submit claims to commercial plans, Medicare, Medicaid or TRICARE. It also does not guarantee reimbursement through insurance, an HSA, an FSA or another benefit arrangement. These statements do not establish a blanket prohibition on enrollment by insured people; they establish that reimbursement should not be assumed.

Sources: [13]

Will I know the pharmacy and exact preparation before ordering?

The consulted pages do not establish that timing. They say formulation and pharmacy depend on clinical review, location and fulfillment availability, and no particular pharmacy is guaranteed. Request the pharmacy identity, complete formulation and relevant instructions before using a dispensed product. Public documentation reviewed here does not identify every pharmacy or establish independent verification of its licensing or preparation-specific testing.

Sources: [6] [13]

If I cancel before shipment, will Third Avenue refund me?

Not necessarily. For an order requiring a new prescription, the policy generally makes it final after clinical approval and prescription issuance, even before pharmacy transmission or shipment, subject to exceptions. An existing-prescription refill has a different boundary: submission to or acceptance for pharmacy processing. The policy provides a refund for a charged renewal canceled before submission for pharmacy processing.

Sources: [7]

What should I do if a Third Avenue injectable delivery is warm?

FDA advises not using an injectable GLP-1 product that arrives warm or with inadequate refrigeration and contacting the provider or dispensing pharmacy. Third Avenue’s refund policy calls for immediate reporting, generally within 48 hours after confirmed delivery, despite the homepage’s seven-day description. Its support email is support@thirdavenue.com. Reporting promptly does not itself guarantee a refund or replacement.

Sources: [1] [7] [8] [5]

Our assessment

Third Avenue documents a recognizable access model: online intake, independent clinical review, compounded injectable medication, pharmacy fulfillment and continuing support funded partly through a separate annual membership. Its terms usefully distinguish the platform from the professionals responsible for care. The evidence is less complete where a prospective patient most needs precision: the exact preparation and pharmacy, support timing, applicable medication price, collection interval and shipping terms. Published refund boundaries also arrive earlier than shipment, and conflicting delivery-reporting deadlines warrant clarification. The balanced conclusion is that Third Avenue’s documentation supports its description as a GLP-1 access platform, not a finding of provider-specific clinical effectiveness. A decision should rest on the actual prescription, responsible professionals and confirmed transaction terms—not borrowed trial results or the lowest displayed price.

Visit Third Avenue’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Third Avenue Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the product, not the ingredient name

02The platform, medical group and pharmacy have different jobs

03Trial evidence does not become Third Avenue outcome evidence

04Published prices need a billing-calendar explanation

05Online intake is a review process, not prescription approval

06Follow-up is described more clearly than its timing

07Payment precedes review, and refund boundaries arrive early

08Shipping promises need a usable problem-resolution plan